77 results
Renal denervation in China: momentum, insights, and evolution
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session highlights the rapidly evolving clinical experience of renal denervation (RDN) in China following regulatory approval, with a focus on real-world practice and programme development.
It reviews how structured, patient-centred hypertension pathways are being integrated with RDN, alongside practical strategies for managing complex renal...
Renal denervation 360°: are you ready for the future?
20 May 2026 – From EuroPCR 2026
Where does renal denervation (RDN) stand today, and where is it heading next?
This EuroPCR 2026 session provides a comprehensive update on RDN, covering its safe and effective use in line with the latest European recommendations. Faculty members share practical guidance on patient selection, programme implementation, and...
IBERIS: the first radial renal denervation (RDN) system for the treatment of uncontrolled hypertension
20 May 2026 – From EuroPCR 2026
This session introduces the IBERIS system, the first radial-access platform for renal denervation in patients with uncontrolled hypertension. It covers patient selection, procedural planning, and key technical considerations for both transfemoral and transradial approaches. A LIVE case demonstration highlights essential procedural steps while addressing the clinical...
Interventions for hypertension: latest developments
20 May 2026 – From EuroPCR 2026
This session reviews the latest developments in interventional treatments for hypertension, focusing on renal denervation (RDN) technologies and clinical outcomes. It includes comparative procedural data from global registries and studies, novel computational assessments, and applications in specific patient populations such as those with polycystic kidney disease...
Interventional therapy for hypertension
19 May 2026 – From EuroPCR 2026
This session addresses interventional therapies for hypertension, emphasizing patient selection for renal denervation and integration of this technique within comprehensive hypertension management. It also reviews available renal denervation technologies, optimal procedural approaches, and considerations for interventional treatment of renal artery stenosis.
How to face resistent hypertension: when pharmacological treatment is not an option
19 May 2026 – From EuroPCR 2026
Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.
Rapid fire session on vascular innovation, interventional technologies and hypertension
18 May 2026 – From EuroPCR 2026
This rapid fire session showcased cutting-edge innovations in vascular interventions, interventional technologies, and hypertension management. Highlights included three-dimensional OCT-guided ultrafast laser atherectomy for calcified lesions, a novel biodegradable metallic stent, intelligent pressure-controlled perfusion to prevent acute limb ischemia, a microneedle balloon catheter, personalized arterial hypertension control...
Renal denervation today and tomorrow
11 Dec 2025 – From GulfPCR-GIM 2025
Renal denervation is re-emerging as a valuable therapeutic option for selected patients with hypertension.
This session explores how current evidence, consensus statements, and guidelines inform patient selection for ultrasound renal denervation, while providing practical insight into how the procedure is performed in daily practice.
Beyond the technical aspects,...
Concept, techniques, and clinical effectiveness of renal denervation in hypertension
03 Dec 2025
Renal denervation has been proven to be safe and effective in lowering blood pressure, supported by trials, included in guidelines, with an overview of catheters, procedure, and patient selection guidance. Enjoy the newest chapter authored by L. Lauder and F. Mahfoud.
Authors :
New frontier in renal denervation: data, devices and developments
22 May 2025 – From EuroPCR 2025
Advance your understanding of renal denervation with the latest data, innovative devices, and emerging developments. This session reviews the 12-month results of the REDUCED 1 trial evaluating the TIVUS system, explores safety and efficacy of novel renal stimulation techniques, and presents outcomes from registries including patients...